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Abstract Lipoprotein(a) (Lp(a)) is an independent cardio-
vascular risk factor playing a causal role for atherosclerotic
cardiovascular disease (CVD). Lipoprotein apheresis (LA)
is a safe well-tolerated outpatient treatment to lower LDL-C
and Lp(a) by 60–70%, and is the ultimate escalating thera-
peutic option in patients with hyperlipoproteinemias (HLP)
involving LDL particles. Major therapeutic effect of LA
is preventing cardiovascular events. Lp(a)-HLP associated
with progressive CVD has been approved as indication for
regular LA in Germany since 2008. The Pro(a)LiFe-study
investigated with a prospective multicenter design the long-
term preventive effect of LA on incidence rates of cardio-
vascular events prospectively over a period of 5 years in
170 consecutive patients who commenced regular LA. Dur-
ing a median period of 4.7 years of the pre-LA period, Lp(a)
associated progressive CVD became apparent. Apolipopro-
tein(a) (apo(a)) isoforms and polymorphisms at the apo(a)
gene (LPA) were analyzed to assess hypothetical clinical
correlations. 154 patients (90.6%) completed 5-years fol-
low-up. Significant decline of the mean annual major ad-
verse cardiac event (MACE) rate was observed from 0.41 ±
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0.45 two years prior to regular LA to 0.06 ± 0.11 during
5 years with regular LA (p < 0.0001). 95.3% of patients
expressed at least one small apo(a) isoform. Calculation
of isoform specific concentrations allowed to confirm the
equivalence of 60 mg/dl or 120 nmol/l as Lp(a) thresholds
of the German LA guideline. Results of 5 years prospec-
tive follow-up confirmed that LA has a lasting effect on
prevention of cardiovascular events in patients with Lp(a)-
HLP and afore progressive CVD.
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Background
Lipoprotein(a) (Lp(a)), consisting of an LDL particle and
apolipoprotein(a) (apo(a)) was first described in 1963. It
took almost 50 years to become fully clear that high Lp(a)
concentrations represent an independent and causal risk fac-
tor for atherosclerotic cardiovascular disease (CVD) [2, 3].
A characteristic of Lp(a) is the more than 1000-fold range of
plasma concentrations between individuals from less than
0.1 mg/dl to more than 300 mg/dl with a skewed distribution
in most populations [2]. Lp(a) concentrations are mainly
under genetic control by the LPA gene locus and here espe-
cially by a size polymorphism of apo(a), caused by a vari-
able number of kringle IV (KIV) repeats in the LPA gene.
The high homology of apo(a) and plasminogen in accord
with clinical observations indicates that high levels of Lp(a)
might additionally exert thrombogenic effects.
Lipoprotein apheresis (LA) is the ultimate escalating op-
tion to lower blood LDL-cholesterol (LDL-C) levels in se-
vere hypercholesterolemia. Since 2008 Lp(a)-HLP has been
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implemented in guidelines of statutory health insurance
funds in Germany as separate indication for LA. Candi-
date patients must have Lp(a) levels >60 mg/dl along with
progressive CVD despite effective treatment of all other
cardiovascular risk factors in particular LDL-C [4]. Ger-
man authorities with their decision stipulated that additional
prospective data were required to justify maintenance of this
reimbursement guideline. The resulting ethical dilemma to
withhold reimbursed LA in such high-risk patients in a ran-
domized controlled trial was inextricable. The design of
the Pro(a)LiFe study was the best possible way to generate
new prospective data in this situation. All elements of the
prospective analysis were conceived before the study was
executed, including the design of the research plan, and se-
lection of the appropriate LA patient population. Compar-
ison of the incidence of cardiovascular events in patients
with Lp(a)-HLP and progressive CVD with a pre-defined
uniform observation period retrospectively 2 years before
and prospectively 5 years after commencing chronic LA
was posed as endpoint [1, 5].
Lp(a)-HLP associated CVD
The German reimbursement guideline permits LA for pa-
tients with Lp(a) > 60 mg/dl, LDL-C in normal range,
and persisting progressive CVD in coronary, peripheral,
or cerebral vascular beds. Normal range of LDL-C should
be in accord with current guidelines for the treatment of
hypercholesterolemia defining risk-associated target levels
Fig. 1 Clinical course of patients with progressive CVD associated with Lp(a)-HLP in the Pro(a)LiFe study. Mean annual rates of MACE
(major adverse cardiac event, i. e. cardiovascular death, nonfatal myocardial infarction, coronary bypass surgery, percutaneous coronary inter-
vention,or stent) in dark orange bars. Light orange bars depict MACE plus disease progression detected by imaging techniques accounted as
equivalent event. Progression of CVD without clinical event was accounted as equivalent event with the following findings: incidence of new
or additional CVD at a new vascular location or region, or deterioration of existing CVD, e. g. 2-vessel CAD progressed to 3-vessel CAD, new
appearance of stenosis or plaques within an already affected vessel or vessel region, >20% deterioration of existing stenosis, appearance of in-stent
stenosis, or stenosis in artery bypass. MACE, major adverse cardiac event; CVD, cardiovascular disease; LA, lipoprotein apheresis; Lp(a)-HLP,
Lp(a)-hyperlipoproteinemia
for LDL-C [6]. According to current practice the follow-
ing conditions carry weight for assessing the individual
risk profile to approve the indication for LA by commit-
tees of regional associations of statutory health insurance
physcians: progressive CVD as documented clinically and
with imaging techniques, established maximally tolerated
lipid lowering drug treatment, recent cardiovascular events
despite optimized treatment of cardiovascular risk, out of
the ordinary frequency of cardiovascular events, early CVD
in the patient, or positive family history of early CVD. It
should be noted, that an acute event alone would not fulfill
requirements of the guideline, and also a recent acute event
is no prerequisite for approval. Careful consideration of
the entire clinical course after diagnosis of CVD is manda-
tory. In Pro(a)LiFe patients it took a median period of
4.7 years before patients were recognized to have Lp(a)-
HLP associated progressive CVD, and LA was initiated
[1].
Prospective 5-years results of the Pro(a)LiFe study
170 patients commencing LA due to Lp(a)-HLP with
Lp(a) > 60 mg/dl and progressive CVD were enrolled in
the Pro(a)LiFe-study [5]. 154 patients (90.6%) completed
the prospective follow-up of 5 years [1]. At baseline con-
comitant hypercholesterolemia was well controlled with
a mean LDL-C of 98.9 mg/dl ± 38.4 mg/dl, corresponding
to a mean corrected LDL-C of 66.3 mg/dl ± 25.4 mg/dl,
suggesting that the cardiovascular benefit substantially de-
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Fig. 2 Frequency of the small
(22 KIV domain copies)
apo(a) allele genotype, or high
risk allele variants tagged by
SNPs rs41055872 or rs3798220
[13], and corresponding mean
Lp(a) concentrations (modified
from [1])
rived from the elimination of elevated concentrations of
Lp(a) particles [1]. LDL-C when directly measured or
calculated by the Friedewald formula includes the contri-
bution of Lp(a) cholesterol, which is estimated as 30% of
the total measured Lp(a) mass of a patient, thus, corrected
LDL-C reflects actually treatable LDL-C. The selection
for Lp(a)-associated progression is strengthened by earlier
observations that in more average cohorts Lp(a)-associ-
ated increase of cardiovascular risk became evident only
with LDL-C concentrations of ≥160 mg/dl [7]. Mean Lp(a)
concentration before regular LA was 108.1 mg/dl and was
reduced by a single LA treatment on average by 68.1%
during 5 years of chronic LA. Median course of the pre-
LA period and mean annual rates of major adverse cardiac
events (MACE) in all 7 study years are depicted in Fig. 1.
Incidence rates for events in all vascular beds revealed an
essentially identical pattern [1]. Increasing event rates in
both years before LA indicated progressive CVD. Regular
LA was associated with a rapid stabilization of progressive
CVD (Fig. 1). In a recent analysis of a large Swedish pop-
ulation cardiovascular risk for the composite endpoint of
nonfatal MI, non-fatal stroke, or cardiovascular death in the
first year after an index myocardial infarction was only 15%
in the high risk subgroup [8]. Therefore, decline in the first
and subsequent years with LA must be regarded as a LA
effect, and is not just reflecting stabilization of vascular
disease after an isolated cardiovascular event. Mean annual
rates of MACE in the first 2 years of prospective follow-up
versus the last 3 years revealed a significant decrease (p <
0.005), indicating the sustaining preventive effect of LA
[1]. The Brisighella Heart Study analysis of mortality in
a primary prevention cohort over 25 years showed a long-
term cardiovascular mortality risk with increasing Lp(a)
[9]. Five deaths due to cardiovascular causes occurred dur-
ing 5 years of follow-up with chronic LA in the Pro(a)LiFe
study, corresponding to a 5-year mortality of 3.0%, only
5 fatal cardiovascular events occurred during 804 patient
years [1].
In three study populations (Copenhagen City Heart
Study, Copenhagen General Population Study from Den-
mark, and ASTRONOMER trial from the US) elevated
Lp(a) levels were associated with increased risk of incident
as well as faster progression of aortic valve stenosis (AVS),
1.8% of subjects with Lp(a) concentrations above 60 mg/dl
had putatively Lp(a) related AVS [10, 11]. There were only
2 patients (1.2%) in the Pro(a)LiFe study with the diagnosis
of AVS. In none of these patients AVS was a prominent
clinical finding.
Characterization of apo(a) genotypes and phenotypes
found a high frequency of patients with small apo(a) iso-
forms associated with increased cardiovascular risk. 95.3%
of patients expressed at least 1 small apo(a) isoform,
which is 4× higher than 23.6% observed in a large sam-
ple of >6000 subjects from 2 population-based studies in
Germany [12]. The frequency of risk alleles tagged by
SNPs rs3798220 or rs10455872 was markedly increased
in Pro(a)LiFe patients ([1, 13]; Fig. 2). However, 35.2%
of the clinically recognized, highly selected Pro(a)LiFe
patients with a small apo(a) phenotype were not tagged
by either of these SNPs. At the individual level there was
a strong effect that the smaller allele was the major iso-
form in plasma (i. e. ≥60% of patients’ total Lp(a)). In
heterozygous patients 46.3% only expressed the smaller
allele, 41.5% expressed the smaller one as major one, 7.3%
showed equal expression, and in 4.9% the larger allele was
the major one. Although in most patients small isoforms
accounted for the high Lp(a) level, in a few cases (4.7%
of patients), large isoforms were solely responsible for the
elevated Lp(a), but patients were clinically indistinguish-
able (Fig. 2). Consequently, our results in summary do not
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Fig. 3 Lp(a) levels of Pro(a)LiFe patients in mg/dl (136 patients with available K4 domain PCR data) and in nmol/l (134 patients with available
isoform specific Lp(a) concentration) after conversion with KIV/2 copy repeat number specific conversion factors according to percentage contri-
bution of isoforms to patients’ total Lp(a). Conversion factors were calculated based on the following assumptions: (1) constant lipid composition
of LDL particles, (2) Lp(a) total protein consists of apoB of 513 kDa and apo(a) with a molecular weight varying according to the K4 domain
number, (3) composition of Lp(a) except 22% protein (apoB), 5% carbohydrate, 8% unesterified cholesterol, 38% cholesterol ester, 20% phos-
pholipid, 7% triglyzeride (Preparation methods according to [14]). Resulting isoform specific conversion factors from mg/dl to nmol/l listed in the
format “kringel 4 domain number”/“apo(a) size in kDa”/“conversion factor” (courtesy of S. Marcovina by personal communication): 12/700/2.75;
13/712/2.70; 14/725/2.65; 15/737/2.61; 16/750/2.56; 17/762/2.52; 18/775/2.48; 19/787/2.44; 20/800/2.40; 21/812/2.37; 22/825/2.33; 23/837/2.30;
24/850/2.26; 25/862/2.23; 26/875/2.20; 27/887/2.17; 28/900/2.14; 29/912/2.11; 30/925/2.08; 31/937/2.05; 32/950/2.03; 33/962/2.00; 34/975/1.97;
35/987/1.95; 36/1000/1.92; 37/1012/1.90; 38/1025/1.88; 39/1037/1.85; 40/1050/1.83; 41/1062/1.81
advise the addition of isoform-associated markers or SNPs
as mandatory criteria to refine the definition of Lp(a)-HLP-
associated progressive CVD in high-risk patient groups.
60 mg/dl threshold for Lp(a) in the German
reimbursement guideline for LA
Lp(a) is a plasma lipoprotein consisting of a cholesterol-rich
LDL particle with one molecule of apolipoprotein B100 and
an additional apo(a) molecule. Apo(a) contains 10 differ-
ent types of plasminogen kringle 4-like repeats as well as
regions homologous to the kringle 5 and protease-P of plas-
minogen. The kringle 4 type 2 domain is present in multiple
repeated copies that differ in number (2 to > 40) between
apo(a) isoforms [2]. Additionally cholesterol, triglyceride,
and phospholipid content as well as the carbohydrate com-
ponent of Lp(a) are not constant resulting in even more
aspects of Lp(a) polymorphism constituting a serious chal-
lenge for the immunochemical measurement of Lp(a) in
plasma [3, 14, 15]. The Lp(a) threshold of 60 mg/dl had
been finally fixed by the German federal authority as crite-
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rion to approve the indication for LA. The need for a molar
equivalent of the mass threshold in the guideline emerged
from recently introduced test systems providing results in
molar units. A pragmatic suggestion was to use 120 nmol/l
as molar equivalent of 60 mg/dl [16]. Measurement of total
Lp(a) mass in mg/dl could only be converted into a molar
unit, if an accurate molecular weight would be available,
however, a general conversion factor from a mass unit into
a molar unit cannot exist for Lp(a) [15, 17]. Molecular
analysis of Lp(a) in Pro(a)LiFe patients offered the oppor-
tunity to validate and confirm the equivalence of 60 mg/dl
or 120 nmol/l by calculation of isoform specific concentra-
tions of Lp(a) ([1]; Fig. 3).
Preventive effects of LA
The clinical benefit of LA is preventing cardiovascular
events. The immediate effect of LA is pulsed physical
extracorporeal elimination of apoB-containing lipoproteins
from plasma, including Lp(a) with its load of oxidized
phospholipids (oxPL), which subsequently is replaced by
endogeneous nascent Lp(a).
Superficial erosion of a coronary artery with rupture
of a plaque’s fibrous cap is thought to cause the major-
ity of acute coronary syndromes [18]. A fibrous cap typi-
cally overlies a lipid-rich center also known as the necrotic
core. Ruptured plaques tend to have large lipid cores and
abundant inflammatory cells. At the tissue level improving
plaque morphology could be another mechanism of pre-
venting clinical events by LA, quantitatively reducing the
number of vulnerable plaques, and qualitatively limiting the
propensity of plaques to rupture [18, 19].
Lp(a) is the major lipoprotein carrier of pro-inflamma-
tory oxPL inducing monocyte trafficking to the arterial wall,
thus reinforcing the hypothesis that the content of oxPL on
Lp(a) is an important biological mediator of the enhanced
atherogenicity of Lp(a) [20, 21]. Lp(a) and oxPL are found
in human atheromas, but more importantly, they are en-
riched in more advanced plaques compared with early le-
sions. MCP-1, an important chemokine implicated in the
development of atherosclerosis, binds to oxidized LDL in
an oxPL dependent manner, and is found on human Lp(a)
as well [20, 22]. As a clinical correlate to these basic inves-
tigations, oxPLs measured on apo B-100, which primarily
reflect the content of oxPLs on Lp(a), strongly predicts
anatomical disease in a variety of vascular beds as well as
cardiovascular events such as cardiac death, MI, stroke, and
peripheral arterial disease [22]. High Lp(a) levels and small
apo(a) sizes are associated with endothelial dysfunction.
A single LA treatment improves endothelium dependent
vasodilation, and the elimination of oxidized Lp(a) might
be more important to this effect than oxidized LDL [1].
Conclusion
Results of the 5-years follow-up of the prospective
Pro(a)LiFe study support that prevention of cardiovas-
cular events is a rapid and lasting effect of LA in patients
with progressive CVD associated with Lp(a)-HLP. Regu-
lar LA had reverted an accelerated progressive course of
CVD to a stable course in terms of the incidence rates of
cardiovascular events and mortality. Patients were charac-
terized by abundant expression of small apo(a) isoforms
which have been associated with increased cardiovascular
risk, although, besides elevated Lp(a) plasma concentra-
tion, selection of this patient cohort was solely based upon
clinical criteria. Calculation of isoform specific concen-
trations allowed to confirm the equivalence of 60 mg/dl
and 120 nmol/l as Lp(a) thresholds in the German LA
guideline. Measurement of Lp(a) concentration must be
recommended to assess individual cardiovascular risk, and
to consider extracorporeal clearance of Lp(a) by LA as
treatment option for select high-risk patients.
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